Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

DBA/2 mouse as an animal model for anti-influenza drug efficacy evaluation.

Kim JI, Park S, Lee S, Lee I, Heo J, Hwang MW, Bae JY, Kim D, Jang SI, Park MS, Park MS.

J Microbiol. 2013 Dec;51(6):866-71. doi: 10.1007/s12275-013-3428-7. Epub 2013 Dec 19.

PMID:
24385366
2.

Mammalian pathogenesis of oseltamivir-resistant pandemic (H1N1) 2009 influenza virus isolated in South Korea.

Kwon D, Shin K, Kim SJ, Lee JY, Kang C.

Virus Res. 2014 Jun 24;185:41-6. doi: 10.1016/j.virusres.2014.03.014. Epub 2014 Mar 19.

PMID:
24657788
3.

Reduction of Neuraminidase Activity Exacerbates Disease in 2009 Pandemic Influenza Virus-Infected Mice.

Ranadheera C, Hagan MW, Leung A, Collignon B, Cutts T, Theriault S, Embury-Hyatt C, Kobasa D.

J Virol. 2016 Oct 14;90(21):9931-9941. Print 2016 Nov 1.

4.

Virus susceptibility and clinical effectiveness of anti-influenza drugs during the 2010-2011 influenza season in Russia.

Leneva IA, Burtseva EI, Yatsyshina SB, Fedyakina IT, Kirillova ES, Selkova EP, Osipova E, Maleev VV.

Int J Infect Dis. 2016 Feb;43:77-84. doi: 10.1016/j.ijid.2016.01.001. Epub 2016 Jan 9.

5.

The NF-kappaB inhibitor SC75741 protects mice against highly pathogenic avian influenza A virus.

Haasbach E, Reiling SJ, Ehrhardt C, Droebner K, R├╝ckle A, Hrincius ER, Leban J, Strobl S, Vitt D, Ludwig S, Planz O.

Antiviral Res. 2013 Sep;99(3):336-44. doi: 10.1016/j.antiviral.2013.06.008. Epub 2013 Jun 28.

PMID:
23811282
6.

Efficacy of a single intravenous administration of laninamivir (an active metabolite of laninamivir octanoate) in an influenza virus infection mouse model.

Kakuta M, Kubo S, Tanaka M, Tobiume S, Tomozawa T, Yamashita M.

Antiviral Res. 2013 Oct;100(1):190-5. doi: 10.1016/j.antiviral.2013.08.004. Epub 2013 Aug 15.

PMID:
23954190
7.

GFP-expressing influenza A virus for evaluation of the efficacy of antiviral agents.

Kim JI, Park S, Lee I, Lee S, Shin S, Won Y, Hwang MW, Bae JY, Heo J, Hyun HE, Jun H, Lim SS, Park MS.

J Microbiol. 2012 Apr;50(2):359-62. doi: 10.1007/s12275-012-2163-9. Epub 2012 Apr 27.

PMID:
22538668
8.

Increased virulence of neuraminidase inhibitor-resistant pandemic H1N1 virus in mice: potential emergence of drug-resistant and virulent variants.

Song MS, Hee Baek Y, Kim EH, Park SJ, Kim S, Lim GJ, Kwon HI, Pascua PN, Decano AG, Lee BJ, Kim YI, Webby RJ, Choi YK.

Virulence. 2013 Aug 15;4(6):489-93. doi: 10.4161/viru.25952. Epub 2013 Aug 2.

9.

A single intramuscular injection of neuraminidase inhibitor peramivir demonstrates antiviral activity against novel pandemic A/California/04/2009 (H1N1) influenza virus infection in mice.

Bantia S, Kellogg D, Parker C, Upshaw R, Ilyushina NA, Babu YS.

Antiviral Res. 2011 Apr;90(1):17-21. doi: 10.1016/j.antiviral.2011.02.001. Epub 2011 Feb 21.

PMID:
21316393
10.

H1N1 influenza A virus neuraminidase modulates infectivity in mice.

Ferraris O, Escuret V, Bouscambert M, Casalegno JS, Jacquot F, Raoul H, Caro V, Valette M, Lina B, Ottmann M.

Antiviral Res. 2012 Mar;93(3):374-80. doi: 10.1016/j.antiviral.2012.01.008. Epub 2012 Feb 1.

PMID:
22321413
11.
12.

Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein.

Triana-Baltzer GB, Gubareva LV, Nicholls JM, Pearce MB, Mishin VP, Belser JA, Chen LM, Chan RW, Chan MC, Hedlund M, Larson JL, Moss RB, Katz JM, Tumpey TM, Fang F.

PLoS One. 2009 Nov 6;4(11):e7788. doi: 10.1371/journal.pone.0007788.

13.

Immunization with live virus vaccine protects highly susceptible DBA/2J mice from lethal influenza A H1N1 infection.

Dengler L, May M, Wilk E, Bahgat MM, Schughart K.

Virol J. 2012 Sep 19;9:212. doi: 10.1186/1743-422X-9-212.

14.

Antiviral activity of SA-2 against influenza A virus in vitro/vivo and its inhibition of RNA polymerase.

Yu J, Wang D, Jin J, Xu J, Li M, Wang H, Dou J, Zhou C.

Antiviral Res. 2016 Mar;127:68-78. doi: 10.1016/j.antiviral.2016.01.011. Epub 2016 Jan 21.

PMID:
26802558
15.

In vitro and in vivo efficacy of fluorodeoxycytidine analogs against highly pathogenic avian influenza H5N1, seasonal, and pandemic H1N1 virus infections.

Kumaki Y, Day CW, Smee DF, Morrey JD, Barnard DL.

Antiviral Res. 2011 Nov;92(2):329-40. doi: 10.1016/j.antiviral.2011.09.001. Epub 2011 Sep 8.

16.

Treatment of influenza A (H1N1) virus infections in mice and ferrets with cyanovirin-N.

Smee DF, Bailey KW, Wong MH, O'Keefe BR, Gustafson KR, Mishin VP, Gubareva LV.

Antiviral Res. 2008 Dec;80(3):266-71. doi: 10.1016/j.antiviral.2008.06.003. Epub 2008 Jul 2.

17.

Differential host determinants contribute to the pathogenesis of 2009 pandemic H1N1 and human H5N1 influenza A viruses in experimental mouse models.

Otte A, Sauter M, Alleva L, Baumgarte S, Klingel K, Gabriel G.

Am J Pathol. 2011 Jul;179(1):230-9. doi: 10.1016/j.ajpath.2011.03.041. Epub 2011 May 18.

18.

Neuraminidase Activity and Resistance of 2009 Pandemic H1N1 Influenza Virus to Antiviral Activity in Bronchoalveolar Fluid.

Ruangrung K, Suptawiwat O, Maneechotesuwan K, Boonarkart C, Chakritbudsabong W, Assawabhumi J, Bhattarakosol P, Uiprasertkul M, Puthavathana P, Wiriyarat W, Jongkaewwattana A, Auewarakul P.

J Virol. 2016 Apr 14;90(9):4637-46. doi: 10.1128/JVI.00013-16. Print 2016 May.

19.

Combination effects of peramivir and favipiravir against oseltamivir-resistant 2009 pandemic influenza A(H1N1) infection in mice.

Park S, Kim JI, Lee I, Lee S, Hwang MW, Bae JY, Heo J, Kim D, Jang SI, Kim H, Cheong HJ, Song JW, Song KJ, Baek LJ, Park MS.

PLoS One. 2014 Jul 3;9(7):e101325. doi: 10.1371/journal.pone.0101325. eCollection 2014.

20.

Evaluation of a fully human monoclonal antibody against multiple influenza A viral strains in mice and a pandemic H1N1 strain in nonhuman primates.

Song A, Myojo K, Laudenslager J, Harada D, Miura T, Suzuki K, Kuni-Kamochi R, Soloff R, Ohgami K, Kanda Y.

Antiviral Res. 2014 Nov;111:60-8. doi: 10.1016/j.antiviral.2014.08.016. Epub 2014 Sep 16.

PMID:
25218949

Supplemental Content

Support Center